A Pilot Study of the Thrombopoietin-Receptor Agonist Eltrombopag in Refractory Aplastic Anemia Patients

NCT00922883 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

43

Enrollment

NIH

Sponsor class

Conditions

Anemia, Aplastic
Anemia, Hypoplastic
Thrombocytopenia

Interventions

DRUG: Eltrombopag

Sponsor

National Heart, Lung, and Blood Institute (NHLBI)